Matthew Unknown's questions to Krystal Biotech Inc (KRYS) leadership • Q2 2025
Question
Matthew, on behalf of Alex Stranhan at Bank of America, asked about the revised timeline for the cystic fibrosis data readout and the expected number and type of patients in that update.
Answer
President of R&D Suma Krishnan attributed the timeline shift to year-end to administrative delays in activating new TDN clinical trial sites. Chairman & CEO Krish Krishnan clarified the goal is to present molecular data from three null mutation patients.